Monday, 25 Mar 2019

You are here

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect. It is known that this loss of response is associated with reduced serum pegloticase levels (https://arthritis-research.biomedcentral.com/articles/10.1186/ar4497).

The investigators of the TRIPLE trial pose the question of whether an additional dose of 8 mg of pegloticase given in between the first and second doses would help to maintain serum pegloticase levels and therefore persistent urate lowering effect.

Dr. Kenneth Saag presented data from the TRIPLE study this morning. This is a multi-center, open label trial enrolling patients with chronic gout unable to maintain a serum uric acid level of 6 mg/dL or less. After discontinuing their background urate lowering agents, subjects received 3 weekly infusions of pegloticase 8 mg followed by biweekly doses to total 10 doses over 17 weeks. sUA was measured just before each dose and subsequent doses were given only if levels remained ≤6mg/dL. Serum pegloticase levels were also measured before each dose.

 

Results for the first 50 subjects were presented and included 22 responders, 21 non-responders and 7 subjects who dropped out. They found that subjects who responded had higher trough levels of pegloticase, and that levels 1-week post-infusion predicted responsiveness to the drug, with an overall response rate of 44% in subjects who received the additional dose. I think we will all be anxiously awaiting more results of this study!

Add new comment

More Like This

Ironwood Retreats from the US Gout Market

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

Allopurinol Reduces Cardiovascular Outcomes in Diabetes

A Canadian study has shown that elderly diabetics who take allopurinol have a significant reduction in cardiovascular outcomes.  

Hyperuricemia has been shown to be a biomarker for cardiovascular outcomes in multiple disorders. These investigators studied the effect of allopurinol and mortality on CV outcomes in a population-based retrospective cohort study from Ontario, Canada.

FDA Slaps a Boxed Warning on Febuxostat for CV Risk

The U.S. Food and Drug Administration (FDA) has reviewed data from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial and concluded there is an increased risk of death with Uloric (febuxostat) compared with allopurinol, and has added this as a boxed warning to the drug’s product label.

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote